To pass the nearly 180 days she was a patient in Seattle Children’s Cancer Unit with graft-versus-host disease (GVHD), London Bowater took orders from her doctors, nurses and other patients and families for friendship bracelets that she would braid from her hospital bed.
Magnetic resonance imaging appears to be safe for patients with cardiac implantable electronic devices, even for chest imaging, according to a new study by researchers from the Intermountain Medical Center Heart Institute.
UNC School of Medicine cardiologist Anil Gehi, MD, will use a $1.7 million grant from the Bristol-Myers Squibb Foundation to further innovate a care model, launched in 2015, that reduced hospitalizations for patients with atrial fibrillation (Afib) presenting in the emergency room by more than 30 percentage points in its first year.
• Among hemodialysis patients admitted to the hospital, nearly a quarter of admissions were followed by an unplanned readmission within 30 days. • Most readmissions were for a diagnosis different than the one for the initial hospitalization. • A small proportion of patients accounted for a disproportionate number of readmissions.
A team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and Weill-Cornell Medical College have identified, for the first time, a new molecular pathway that is required for acute myeloid leukemia (AML) development. This work could provide a rationale for targeting the RNA methylation program in myeloid leukemia.
UVA has administered its first dose of an experimental gene therapy for a deadly form of treatment-resistant pediatric leukemia.
A genetic fault has been identified in people with an aggressive type of leukaemia that can significantly affect how they respond to treatment.
A new study finds that genetic testing can help determine the safest dose of the blood thinner warfarin, with fewer side effects, in patients undergoing joint replacement surgery.
A new study led by Washington University School of Medicine in St. Louis shows that dosing warfarin (Coumadin and others) is safer — producing fewer adverse events such as hemorrhage — when key elements of a patient’s genetic makeup are considered.
The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies.
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.
NCCN 12th Annual Congress: Hematologic Malignancies™ will be held October 6 – 7, 2017 in San Francisco, California, and features a new Nursing Forum.
Investigators at CHLA have identified the molecular pathway used to foster neuroblastoma and demonstrated use of a clinically available agent, ruxolitinib, to block the pathway.
Scientists have found that ignored pieces of DNA play a critical role in the development of immune cells (T cells). These areas activate a change in the structure of DNA that brings together crucial elements necessary for T cell formation. This “big bang” discovery may aid in combating diseases.
People with both high and low levels of magnesium in their blood may have a greater risk of developing dementia, according to a study published in the September 20, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Chicago (Sep. 20, 2017): The Association of Pediatric Hematology/Oncology Nurses (APHON) has awarded this year’s Dr. Patricia Greene Leadership Award to Amy Haskamp, MSN CNS RN CPON®. Haskamp was presented with this award at the 41st Annual APHON Conference and Exhibit, held August 17 -19, 2017 in Palm Springs, CA.
Chicago (Sep. 20, 2017): The Association of Pediatric Hematology/Oncology Nurses (APHON) has presented Jami Gattuso, MSN RN CPON® with the 2017 Dr. Casey Hooke Distinguished Service Award. Gattuso received her award at the 41st APHON Annual Conference and Exhibit, held August 17 – 19 in Palm Springs, CA. This award is presented to an APHON member who has demonstrated excellence to service and to leadership of APHON.
Chicago (Sep. 20, 2017): The Association of Pediatric Hematology/Oncology Nurses (APHON) has awarded Dianne Fochtman, PhD RN CPNP CHPPN CPON® with the 2017 Dr. Nancy E. Kline Mentoring Award. This award was presented to Fochtman at the 41st Annual APHON Conference and Exhibit, on August 18 in Palm Springs, CA.
Chicago (Sep. 20, 2017) The Association of Pediatric Hematology/Oncology Nurses (APHON) announced the recipients of the 2017 APHON Membership Awards at its 41st Annual Conference and Exhibit, held August 17-19 in Palm Springs, CA. APHON Membership Awards recognize members who have shown outstanding achievement in their field.
Chicago (Sept. 20, 2017): The Association of Pediatric Hematology/Oncology Nurses (APHON) elected Susan Burke, MA RN CPNP CPHON®, to serve as President for the 2017-2019 term. Burke officially took office at the recent 41st Annual APHON Conference and Exhibit, held August 17-19 in Palm Springs, CA.
Researchers at Joslin Diabetes Center have identified an unexpected natural protective factor against chronic inflammation that drives cardiovascular disease in type 2 diabetes.
A Ludwig Cancer Research study has uncovered a new mechanism by which cancer cells evade destruction by the immune system. The paper, led by Camilla Jandus of the Lausanne Branch of the Ludwig Institute for Cancer Research, describes how immune cells known as group 2 innate lymphoid cells (ILC2s) are recruited by leukemic cells to suppress an essential anticancer immune response.
Scientists have helped provide a way to better understand how to enable drugs to enter the brain and how cancer cells make it past the blood brain barrier.
Brandon Hudgins, professional long-distance runner, GPA/Wegener’s patient and leader of VF Team Brandon, has shared his story in his recently released book, “Going the Distance: The Journey of a Vasculitis Patient on the Road to Olympic Glory.”
There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease.
Monroe Carell Jr. Children’s Hospital at Vanderbilt is part of a select group of health care institutions recently chosen to offer a new FDA-approved immunotherapy for a subset of pediatric acute lymphoblastic leukemia (ALL).
Leukemia survivor Jeffrey Hoffman owes his life to a complete stranger who altruistically donated bone marrow cells for Mr. Hoffman's successful bone marrow transplant. "It was a very noble thing to do," Mr. Hoffman said. On September 10, 2017, Mr. Hoffman (left) met his donor, Zachary Gold (right), for the first time, during Loyola Medicine's Bone Marrow TransplantCelebration of Survivorship. About 400 patients, family members, caregivers, donors, doctors and nurses attended the annual event at Loyola’s Cardinal Bernardin Cancer Center.
The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML).
St. Jude Children’s Research Hospital investigators report preventive antibiotic therapy, particularly with levofloxacin, reduced the odds of infections in at-risk pediatric leukemia patients early in cancer treatment
Waking up in the morning with the joint pain, swelling and stiffness that accompanies lupus doesn’t exactly inspire a workout. But research in mice and a related pilot study in humans are showing how regular activity and stress reduction could lead to better health in the long run.
An electronic alert system helps clinicians quickly do a bedside assessment to identify children with severe sepsis in an emergency department. Researchers from Children’s Hospital of Philadelphia report on their efforts to rapidly recognize this life-threatening condition.
A chemically modified version of the common blood thinner heparin may be the first promising method of preventing the harmful cascade of destruction to brain tissue that commonly follows traumatic brain injury (TBI), according to new research findings. Though there is currently no drug therapy to prevent the repercussions that can occur in the days and weeks after TBI, researchers at the Perelman School of Medicine at the University of Pennsylvania showed that mice treated with a modified version of heparin with very low coagulant activity (known as 2-O, 3-O desulfated heparin, ODSH or CX-01) had less brain swelling and inflammation, and less evidence of brain damage, compared to mice that received saline.
Alina Franke registered to donate her bone marrow in Hamburg, Germany, in 2009. She wound up being the one person in 24 million around the world on the Be The Match registry to be the perfect match that Jimmy Roberson needed.
Biomedical engineers have developed a microfluidic test that could enable rapid diagnosis and early intervention for sepsis, which accounts for the most deaths and medical expenses in hospitals worldwide.
A five-year effort across the Johns Hopkins Health System to reduce unnecessary blood transfusions and improve patient care has also resulted in an annual cost savings of more than $2 million, researchers report.
The grant provides support for an innovative clinical trial that seeks to compare outcomes for young patients with newly diagnosed severe aplastic anemia – comparing the use of unrelated-donor blood and marrow transplant to immune suppression therapy.
TAMPA, Fla. – Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus (HPV) vaccines has significantly reduced the number of those who develop and die from cervical cancer.
University of Colorado Cancer Center study shows that monitoring levels of blood tumor markers may predict when a lung cancer patient is progressing on targeted treatments.
For more than a century, the link between thyroid hormone and red blood cell production has remained elusive. Now, Whitehead scientists have teased about the mechanism that connects them, which could help scientists identify new therapies for specific types of anemia.
Free Cholesterol Health Fairs Offered Throughout New York City
Dr. Pawel Muranski has joined NewYork-Presbyterian and Columbia University Medical Center (CUMC) as director of cellular immunotherapy at the newly established Good Manufacturing Practices (GMP) cell production lab and assistant director of Transfusion Medicine and Cellular Therapy.
The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration.
In a landmark decision for the field of cancer immunotherapy, the U.S. Food and Drug Administration (FDA) today approved a personalized cellular therapy developed by the University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
With a $1.16 million cooperative agreement from the CDC, NIDA, SAMHSA and the Appalachian Regional Commission, April Young, researcher with the University of Kentucky College of Public Health and Center on Drug and Alcohol Research, will partner with communities to conduct research to address the opioid epidemic in 12 Eastern Kentucky counties.
A scientist at Sanford Research studying lung development and disease in premature babies has received a $2,041,195 grant over five years from the National Institutes of Health’s National Heart, Lung and Blood Institute. Peter Vitiello, Ph.D., will study how molecular pathways contribute to lung development and disease in premature babies.
Researchers at Columbia University Medical Center reversed age-related memory loss in mice by boosting blood levels of osteocalcin, a hormone produced by bone cells.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right